$50 Million

Aziyo Biologics

Initial Public Offering

Bookrunner, October 2020

Aziyo Biologics, Inc. is a Healthcare company focused on regenerative medicine in areas such as cardiology, orthopedics, and other specialties. The Company’s mission is to restore health and mobility through the development of innovative new solutions that expand the possibilities of regenerative medicine. Since its founding, the Company has expanded through a combination of acquisitions and strategic partnerships and intends to continue an active business development strategy. Aziyo has a portfolio of core products that spans the implantable electronic devices/cardiovascular market, the orthopedic/spinal repair market and the soft tissue reconstruction market, which represented a combined $3 billion market opportunity in the United States in 2019. The Company estimates that more than two million patients were implanted with medical devices, such as pacemakers, defibrillators, neuro-stimulators, spinal fusion and trauma fracture hardware and tissue expanders for breast reconstruction, in the United States in 2019. The Company’s core products are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

More Like This

Oct 2020
$120 Million

Initial Public Offering

Bookrunner

View Details
Oct 2020
$219 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Oct 2020
$104 Million

Initial Public Offering

Lead Left Bookrunner

View Details